The Living Guidelines: UA/NSTEMI Recommendations for Additional Management Considerations for Antiplatelet and Anticoagulant Therapy Polling Results for CLASS III Guidelines

Any recommendations found on these pages are for education use only. WikiDoc is not a substitute for a licensed healthcare provider. Please see the disclaimers page for important information regarding limitations of the information found here. In suggesting edits to the guidelines, WikiDoc suggests that the following classification scheme be used. Read more about the classification scheme used by the ACC / AHA Guidelines Committee here.

Class III Guidelines
1- Intravenous fibrinolytic therapy is not indicated in patients without acute ST segment elevation, a true posterior MI, or a presumed new left bundle branch block (LBBB). (Class III Level of Evidence: A) 

UA/NSTEMI Guidelines Class III Recommendation 1 for Additional Management Considerations for Antiplatelet and Anticoagulant Therapy should be: CLASS I CLASS IIa CLASS IIb CLASS III